Advertisement

Topics

Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer

08:00 EDT 6 Jun 2017 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
-- Cooperative Research and Development Agreement to Evaluate Activity of Eleven’s Targeted Therapeutic Vicinium in Combination with the Immune Checkpoint Inhibitor Durvalumab -- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO),...

Other Sources for this Article

Stern Investor Relations
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com

NEXT ARTICLE

More From BioPortfolio on "Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...